Proteome | Tumour versus adjacent | ECM-receptor interaction | 8 | 2.62×10−4 |
Proteome | Tumour versus adjacent | Toxoplasmosis | 8 | 2.62×10−4 |
Proteome | Tumour versus adjacent | SCLC | 7 | 2.66×10−4 |
Proteome | Tumour versus adjacent | PI3K–Akt signalling pathway | 8 | 4.25×10−4 |
Proteome | Tumour versus adjacent | Glycolysis/gluconeogensis | 5 | 1.99×10−2 |
Proteome | Tumour versus adjacent | Focal adhesion | 11 | 2.81×10−2 |
Proteome | Tumour versus control | SCLC | 8 | 1.6×10−5 |
Proteome | Tumour versus control | ECM-receptor interaction | 9 | 1.6×10−5 |
Proteome | Tumour versus control | Toxoplasmosis | 9 | 1.6×10−5 |
Proteome | Tumour versus control | PI3K–Akt signalling pathway | 9 | 5.76×10−5 |
Proteome | Tumour versus control | Focal adhesion | 15 | 1.58×10−4 |
Translatome | Adjacent versus control | ECM-receptor interaction | 12 | 3.2×10−6 |
Translatome | Adjacent versus control | Protein digestion and absorption | 7 | 8.85×10−3 |
Translatome | Adjacent versus control | Focal adhesion | 14 | 1.48×10−2 |
Translatome | Adjacent versus control | Bile secretion | 5 | 4.38×10−2 |
Translatome | Adjacent versus control | Dilated cardiomyopathy | 7 | 4.38×10−2 |
Translatome | Adjacent versus control | PI3K–Akt signalling pathway | 15 | 4.6×10−2 |